Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Food and Drug Administration and the Centers for Disease Control and Prevention are recommending a pause in the use of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine, the agencies said in a Tuesday statement, sending the drugmaker's stock lower in premarket trading.  What Happened: Over 6.8 million doses of the vaccine have been administered in the U.S., and there have been reports of six cases of a rare and severe type of blood clot in individuals after receiving the vaccine.

FDA Recommends Pause In Use Of Johnson & Johnson's COVID-19 Vaccine On Blood Clot Concerns

"This is a devastating blow to this J&J vaccine effort in the United States," said Dr. Kavita Patel, a primary care physician in Washington, D.C.

J&J Covid shot pause will delay U.S. vaccination efforts, says Dr. Kavita Patel

Nearly 7 million doses of the vaccine have been administered in the U.S. so far.

U.S. Calls For Halting Johnson & Johnson Covid-19 Vaccine After Rare Blood Clot Cases

So far there have been six reported cases of “a rare and severe type of blood clot” in those who have received the Johnson & Johnson vaccine, according to the FDA. It hasn't been a good few weeks for COVID-19 vaccines.

The FDA tells states to cease use of the Johnson & Johnson vaccine over blood clot fears

The US food and drug administration has recommended a "pause" to the rollout of the Johnson & Johnson COVID vaccine so it can investigate reports of blood clots.

US recommends 'pause' to Johnson & Johnson jab rollout over blood clot fears

The rollout of the Johnson & Johnson COVID vaccine across Europe has been delayed, while US officials have recommended a "pause" in the use of the jab as reports of blood clots are investigated.

European rollout of Johnson & Johnson COVID jab delayed as US officials investigate clots

Futures for the Dow Jones Industrial Average and the S&P 500 pivoted lower Tuesday morning after a report from the New York Times said that the U.S. will seek a pause of the Johnson & Johnson vaccine due to blood-clotting issues. The New York Times, citing officials briefed on the decision, said a rare clotting issue has cropped up in six women within about two weeks of vaccination.

Dow futures turn south Tuesday after report that U.S. is calling for a pause of Johnson & Johnson COVID vaccine

The stock price of Johnson & Johnson (NYSE: JNJ) fell by over 3% pre-market. This is why it happened.

JNJ Stock: Over 3% Decrease Pre-Market Explanation

Federal health agencies will call for an immediate pause in the use of the Johnson & Johnson COVID-19 vaccine later Tuesday, after six recipients in the U.S. developed a rare disorder involving blood clots within roughly two weeks of vaccination, the New York Times reported, citing officials briefed on the decision. The U.S. Food and Drug Administration confirmed the news in a tweet.

Federal health agencies to call for pause in use of J&J vaccine over blood clotting disorder: New York Times

The FDA is asking states to temporarily halt using J&J's Covid-19 vaccine after six people in the U.S. developed a rare blood-clotting disorder.

U.S. regulators call for pause in use of Johnson & Johnson vaccine due to clotting issues

Cardinal Health

Con Ed

Coca-Cola

PepsiCo

Procter & Gamble

AT&T

Unilever

Vanguard High Dividend Yield ETF

Verizon

My dividend stock portfolio was burnt by dividend cuts in 2020 and lost over $800+ in forward dividend income. Therefore, I was ready to get back to basics and acquire more shares in the best quality dividend stocks out there. In total, my dividend stock purchases of VYM totaled $1,485.08, acquiring 15 total shares. This added $45 in forward dividend income.

Dividend Stock Purchase: Lanny's March 2021 Summary

AstraZeneca

BioNTech SE

Moderna

Novavax

Pfizer

Regeneron Pharmaceuticals

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies. The post Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks appeared first on InvestorPlace.

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

Pulmatrix Inc (NASDAQ: PULM) will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson's (NYSE: JNJ) Enterprise Innovation's decision to terminate the license agreement. Pulmatrix intends to continue developing PUR1800 with ongoing clinical and toxicology studies to support programs in acute exacerbations in COPD (AECOPD) and other chronic airway diseases.

Pulmatrix Stock Is Trading Lower After JNJ's Lung Cancer Initiative Terminates PUR1800 Licensing Pact

Emergent BioSolutions, the manufacturer at the center of the Johnson & Johnson coronavirus vaccine bungle, gave its chief executive officer a 51 percent compensation bump in 2020 — bringing his total remuneration to a whopping $5.6 million. On top of a lucrative $893,000 salary, CEO Robert Kramer received a $1.2 million bonus and $3.5 million.

CEO at Johnson & Johnson vaccine plant company got 51% raise in 2020

JNJ shares are consolidating prior gains. With multiple support levels just below and the stock at a middling valuation, I see upside potential.

Johnson & Johnson: Don't Miss This Chance

The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.

J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots

Just as the Biden administration is moving up its deadline to make vaccine eligibility available to all adults by April 19, the supply of at least one of the vaccines, Johnson & Johnson's, is slowing down, and with some of its manufacturing challenges at an independent plant that has had problems in the past, it's unclear exactly when it will pick back up again.

J&J vaccine distribution will slow down by 84% next week

The government has allocated only 700,000 J&J shots to states next week, down from 4.9 million the week prior, according to data from the CDC.

U.S. states face steep decline in J&J vaccine next week as feds work to approve Baltimore plant

More concerns are coming out over the COVID-19 vaccine made by Johnson & Johnson (NYSE: JNJ). What Happened: Health officials in Georgia have temporarily stopped distributing the Johnson & Johnson vaccine at one site in the state's north.

Why Authorities Are Putting The Brakes on Johnson & Johnson's Vaccine In Several States

Johnson & Johnson's coronavirus vaccine rollout hit several unfortunate snags this week — some far worse than others.  The New York Times reported on Tuesday that 62 million of the company's vaccine doses must be checked for contamination, following an error at a Maryland manufacturing plant that already ruined 15 million doses. The plant's workers accidentally mixed up some vaccine ingredients last month.

Johnson & Johnson had a very bad week — but fears of negative reactions and blood clots are likely overblown

Federal Realty Investment Trust

Illinois Tool Works

Lowe's

Dividend stocks can yield powerful results when stretched out for the long term. Here's a look at seven stocks with massive consistency.

7 Dividend Stocks With 50 Years of Dividend Increases

AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now, European Medical Agency (EMA) is investigating potential clotting risks from Johnson & Johnson's (NYSE: JNJ) one-shot COVID-19 vaccine.

Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded

Demand for the vaccine next week will be higher than ever, but the federal government will distribute only 700,000 Johnson & Johnson doses.

Johnson & Johnson Deliveries Plummet 86%—Hampering Vaccination Efforts As States Open Up

European regulators are investigating whether Johnson & Johnson's COVID-19 vaccine caused unusual blood clotting after four cases were reported in vaccine recipients, including one fatality.  The European Medicines Agency's Pharmacovigilance Risk Assessment Committee disclosed Friday that they are reviewing the vaccine after three people who received J&J's vaccine in the US and another who was involved in a clinical trial developed blood clots. It's currently not clear if the vaccine caused these clots.

European regulators are watching Johnson & Johnson's vaccine for unusual blood clots

European regulators are investigating four cases of blood clots with low blood platelets in recipients of Johnson & Johnson's coronavirus vaccine. In response, JNJ stock dipped Friday.

News for Johnson & Johnson Stock (JNJ)